Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.

Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG, OLYMPIA 1 Investigators

Open source

DOI: 10.1001/jamadermatol.2024.4796
Published: 2025 Feb 1
Container: JAMA dermatology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamadermatol.2024.4796,
  title = {Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.},
  author = {Ständer S and Yosipovitch G and Legat FJ and Reich A and Paul C and Simon D and Naldi L and Metz M and Tsianakas A and Pink A and Fage S and Micali G and Weisshaar E and Sundaram H and Metelitsa A and Augustin M and Wollenberg A and Homey B and Fargnoli MC and Sofen H and Korman NJ and Skov L and Chen X and Jabbar-Lopez ZK and Piketty C and Kwatra SG and OLYMPIA 1 Investigators},
  year = {2025},
  journal = {JAMA dermatology},
  doi = {10.1001/jamadermatol.2024.4796},
  url = {https://doi.org/10.1001/jamadermatol.2024.4796}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
AU  - Ständer S
AU  - Yosipovitch G
AU  - Legat FJ
AU  - Reich A
AU  - Paul C
AU  - Simon D
AU  - Naldi L
AU  - Metz M
AU  - Tsianakas A
AU  - Pink A
AU  - Fage S
AU  - Micali G
AU  - Weisshaar E
AU  - Sundaram H
AU  - Metelitsa A
AU  - Augustin M
AU  - Wollenberg A
AU  - Homey B
AU  - Fargnoli MC
AU  - Sofen H
AU  - Korman NJ
AU  - Skov L
AU  - Chen X
AU  - Jabbar-Lopez ZK
AU  - Piketty C
AU  - Kwatra SG
AU  - OLYMPIA 1 Investigators
PY  - 2025
JO  - JAMA dermatology
DO  - 10.1001/jamadermatol.2024.4796
UR  - https://doi.org/10.1001/jamadermatol.2024.4796
ER  -

APA

S, S., G, Y., FJ, L., A, R., C, P., D, S., L, N., M, M., A, T., A, P., S, F., G, M., E, W., H, S., A, M., M, A., A, W., B, H., MC, F., H, S., NJ, K., L, S., X, C., ZK, J., C, P., SG, K., & Investigators, O. 1. (2025). Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.. JAMA dermatology. https://doi.org/10.1001/jamadermatol.2024.4796

Source records

pubmed · retrieved 2026-09-26T04:41:34.563Z
europe-pmc · retrieved 2026-09-26T04:41:34.584Z